Skip to search boxSkip to navigationSkip to main content

Novel strategies against multidrug resistance mediated by p-glycoprotein

*Corresponding author for this work
  • Universidad Popular Autonoma de Puebla
    ,
  • Centro de investigación oncológica-UNE-UPAEP
Research Output:
Contribution to journal
Review article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 169-175 (7 pages)

Journal (Volume, Issue Number)

Drugs of the Future (Volume 41, Issue 3)

Publication milestones

  • Published - 01/03/2016

Publication status

Published - 01/03/2016

ISSN

0377-8282

Publication IDs

  • Scopus: 84973563166

Abstract

P-glycoprotein (P-gp) is an ATP-binding cassette (ABC) protein that mediates the ATP-dependent efflux of hydrophobic toxins. Physiologically, P-gp excretes endogenous metabolites and other xenotoxic substrates into the urine, bile and feces. P-gp is a multidrug resistance (MDR) pump, which exports chemotherapeutic agents from target cells to the extracellular space. P-gp is considered an adverse factor in the prognosis of hematological and solid tumors because efflux of chemotherapeutic drugs reduces their intracellular levels, requiring higher doses to produce an effect equivalent to that before the P-gp overexpression. Effective P-gp modulators must inhibit P-gp activity, avoiding pharmacological interactions and toxicity. Nanoparticle-based advanced delivery systems have been recently studied, showing that these novel strategies can overcome MDR in some cancers.